eligibility_summary
Inclusion: adults ≥18 with untreated CD20+ DLBCL, IPI 2–5, ECOG 0–2, LVEF ≥50%, adequate counts/organ function, ≥1 FDG-avid measurable lesion, biopsy tissue required, HBV/HCV controlled, contraception. Exclusion: drug allergy/anthracyclines, prior transplant, excluded lymphoma types, prior tx beyond ≤7 d steroids or 1 R-CHOP, mediastinal RT, active infection, HIV/HTLV-1, major cardiac/pulmonary/CNS or liver disease, ≥G2 neuropathy/CMT, surgery <4 wks, active autoimmune on therapy, pregnancy/lactation, HLH.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase II single-arm trial in previously untreated high-risk DLBCL combining: Glofitamab (human IgG1 bispecific T-cell–engaging antibody, binds CD20 on B cells and CD3 on T cells to redirect cytotoxic T cells), Polatuzumab vedotin (anti‑CD79b antibody–drug conjugate delivering MMAE, a microtubule inhibitor), and R‑CHP: Rituximab (anti‑CD20 monoclonal antibody mediating ADCC/complement), Cyclophosphamide (alkylating DNA crosslinker), Doxorubicin (anthracycline, DNA intercalation/topoisomerase II inhibition/ROS), Prednisone (glucocorticoid inducing lymphocyte apoptosis). Targets/pathways: malignant CD20+ B cells, B‑cell receptor component CD79b, T‑cell activation via CD3, microtubules (MMAE), DNA replication/repair (alkylation, topo II inhibition), immune effector pathways (ADCC/complement). Primary cells targeted: B‑cell lymphoma, effector T cells are recruited.